Adoram Therapeutics SA

Adoram Therapeutics, a UNIGE spin-off, is discovering small molecule therapies with a sought-after ‘allosteric’ mode of action, providing improved efficacy & safety compared to conventional small molecules. Our foremost asset is an immunotherapy for solid tumors, with additional assets for CNS & inflammatory indications. We leverage in-house expertise including sensitive allosteric screening assays to identify hits that modulate the signaling of G-protein coupled receptors (GPCRs), the largest class of human receptors. We are currently securing a seed round and would like to meet investors & drug development experts who share our passion for best-in-class therapies.